Enteris BioPharma is the partner of choice for developing oral BCS-III and BCS-IV drug products, including oral peptides, peptidomimetics, and small molecules. The Peptelligence® and ProPerma® oral drug delivery technologies have been proven safe and effective in numerous clinical trials, enabling significant treatment opportunities for which there is no oral delivery option. With a purpose-built, state-of-the-art facility, Enteris offers end-to-end oral drug product development from formulation and proof-of-concept to clinical and commercial manufacturing for the most challenging APIs.

Enteris BioPharma white capsules for oral peptide drug delivery.

TECHNOLOGY

The Peptelligence® and ProPerma® technologies provide oral bioavailability enhancement of challenging BCS-III and BCS-IV compounds by uniquely improving both permeability and solubility.

Peptelligence® ProPerma®

CMC CAPABILITIES

Enteris supports our partners through all stages of solid oral dosage form development from formulation and analytical method development to cGMP clinical and commercial manufacturing.

Formulation Development Analytical R&D cGMP MANUFACTURING Quality & Regulatory

PARTNERING

Enteris works with our partners through the various stages of development, from a robust proof-of-concept feasibility program through commercial manufacture utilizing our extensive CMC capabilities.

Oral Feasibility Program Contract Manufacturing